Am J Epidemiol 2003; 157:973-979.
Copyright © 2003 by Johns
Hopkins Bloomberg School of Public Health
ORIGINAL CONTRIBUTIONS |
Changes in Smoking Status Affect Women More than Men: Results of the Lung Health Study
1 Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN.
2 Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
3 Division of Pulmonary and Critical Care Medicine, Oregon Health Sciences University, Portland, OR.
4 School of Medicine, Johns Hopkins University, Baltimore, MD.
5 Pulmonary Division, University of Alabama at Birmingham, Birmingham, AL.
6 School of Medicine, University of Pittsburgh, Pittsburgh, PA.
Lung Health Study participants were smokers aged 35–60 years with mild lung function impairment who participated in a 5-year, 10-center (nine in the United States, one in Canada) clinical trial in 1986–1994. The authors compared the relation of randomized treatment assignments and of smoking history during the study with changes in lung function between men and women. Spirometry was performed annually, and 3,348 men and 1,998 women attended the follow-up clinic visit that included spirometry at year 5. This paper reports on an analysis of changes in lung function by gender, treatment group, and three smoking history categories: sustained quitters, intermittent quitters, and continuing smokers. Among participants who quit smoking in the first year, mean forced expiratory volume in 1 second (FEV1) expressed as a percentage of the predicted value of FEV1 given the person’s age, height, gender, and race (FEV1%) increased more in women (3.7% of predicted) than in men (1.6% of predicted) (p < 0.001). Across the 5-year follow-up period, among sustained quitters, women gained more in FEV1% of predicted than did men. Methacholine reactivity was more strongly related to rates of decline in women than in men (p < 0.001). Therefore, among persons at risk for chronic obstructive pulmonary disease, smoking cessation has an even clearer advantage for women than it does for men.
clinical trials; lung diseases, obstructive; sex; smoking cessation; spirometry
Abbreviations: Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FEV1%, forced expiratory volume in 1 second expressed as a percentage of the predicted value of FEV1 given the person’s age, height, gender, and race.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. D. Sin, S. B.-Z. Cohen, A. Day, H. Coxson, and P. D. Pare Understanding the Biological Differences in Susceptibility to Chronic Obstructive Pulmonary Disease between Men and Women Proceedings of the ATS, December 1, 2007; 4(8): 671 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Dransfield, G. R. Washko, M. G. Foreman, R. S. J. Estepar, J. Reilly, and W. C. Bailey Gender Differences in the Severity of CT Emphysema in COPD Chest, August 1, 2007; 132(2): 464 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ben-Zaken Cohen, P. D. Pare, S. F. P. Man, and D. D. Sin The Growing Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer in Women: Examining Sex Differences in Cigarette Smoke Metabolism Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Soriano, D. D. Sin, X. Zhang, P. G. Camp, J. A. Anderson, N. R. Anthonisen, A. S. Buist, P. S. Burge, P. M. Calverley, J. E. Connett, et al. A Pooled Analysis of FEV1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo Chest, March 1, 2007; 131(3): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Boezen and D. S. Postma Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression? Eur. Respir. J., January 1, 2007; 29(1): 8 - 10. [Full Text] [PDF]
|
|
|
|
|
|
L. Schirnhofer, B. Lamprecht, W. M. Vollmer, M. J. Allison, M. Studnicka, R. L. Jensen, and A. S. Buist COPD Prevalence in Salzburg, Austria: Results From the Burden of Obstructive Lung Disease (BOLD) Study Chest, January 1, 2007; 131(1): 29 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Guenegou, B Leynaert, J Benessiano, I Pin, P Demoly, F Neukirch, J Boczkowski, and M Aubier Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France. J. Med. Genet., August 1, 2006; 43(8): e43 - e43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]
|
|